LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

The HGF/MET signaling pathway regulates a wide variety of normal cellular functions that can be subverted to support neoplasia, including cell proliferation, survival, apoptosis, scattering and motility, invasion, and angiogenesis. MET over-expression (with or without gene amplification), aberrant a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, S. Betty, Peek, Victoria L., Ajamie, Rose, Buchanan, Sean G., Graff, Jeremy R., Heidler, Steven A., Hui, Yu-Hua, Huss, Karen L., Konicek, Bruce W., Manro, Jason R., Shih, Chuan, Stewart, Julie A., Stewart, Trent R., Stout, Stephanie L., Uhlik, Mark T., Um, Suzane L., Wang, Yong, Wu, Wenjuan, Yan, Lei, Yang, Wei J., Zhong, Boyu, Walgren, Richard A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2012
Materias:
Preclinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717159/
https://www.ncbi.nlm.nih.gov/pubmed/23275061
http://dx.doi.org/10.1007/s10637-012-9912-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717159/
https://www.ncbi.nlm.nih.gov/pubmed/23275061
http://dx.doi.org/10.1007/s10637-012-9912-9

Ejemplares similares